Literature DB >> 20432002

The role of advanced imaging techniques in cystic fibrosis follow-up: is there a place for MRI?

Michael Puderbach1, Monika Eichinger.   

Abstract

Cystic fibrosis (CF) lung disease is caused by mutations in the CFTR-gene and remains one of the most frequent lethal inherited diseases in the Caucasian population. Given the progress in CF therapy and the consecutive improvement in prognosis, monitoring of disease progression and effectiveness of therapeutic interventions with repeated imaging of the CF lung plays an increasingly important role. So far, the chest radiograph has been the most widely used imaging modality to monitor morphological changes in the CF lung. CT is the gold standard for assessment of morphological changes of airways and lung parenchyma. Considering the necessity of life-long repeated imaging studies, the cumulative radiation doses reached with CT is problematic for CF patients. A sensitive, non-invasive and quantitative technique without radiation exposure is warranted for monitoring of disease activity. In previous studies, MRI proved to be comparable to CT regarding the detection of morphological changes in the CF lung without using ionising radiation. Furthermore, MRI was shown to be superior to CT regarding assessment of functional changes of the lung. This review presents the typical morphological and functional MR imaging findings with respect to MR-based follow-up of CF lung disease. MRI offers a variety of techniques for morphological and functional imaging of the CF lung. Using this radiation free technique short- and long-term follow-up studies are possible enabling an individualised guidance of the therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20432002     DOI: 10.1007/s00247-010-1589-7

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  33 in total

1.  Analysis of intrapulmonary O(2) concentration by MR imaging of inhaled hyperpolarized helium-3.

Authors:  B Eberle; N Weiler; K Markstaller; H Kauczor; A Deninger; M Ebert; T Grossmann; W Heil; L O Lauer; T P Roberts; W G Schreiber; R Surkau; W F Dick; E W Otten; M Thelen
Journal:  J Appl Physiol (1985)       Date:  1999-12

2.  Lung air spaces: MR imaging evaluation with hyperpolarized 3He gas.

Authors:  E E de Lange; J P Mugler; J R Brookeman; J Knight-Scott; J D Truwit; C D Teates; T M Daniel; P L Bogorad; G D Cates
Journal:  Radiology       Date:  1999-03       Impact factor: 11.105

3.  Dynamic ventilation (3)He-magnetic resonance imaging with lung motion correction: gas flow distribution analysis.

Authors:  Klaus Kurt Gast; Michael Ulrich Puderbach; Ignacio Rodriguez; Balthasar Eberle; Klaus Markstaller; Alexander Thomas Hanke; Joerg Schmiedeskamp; Norbert Weiler; Jana Lill; Wolfgang G Schreiber; Manfred Thelen; Hans-Ulrich Kauczor
Journal:  Invest Radiol       Date:  2002-03       Impact factor: 6.016

Review 4.  MR evaluation of pulmonary blood flow.

Authors:  David L Levin; Hiroto Hatabu
Journal:  J Thorac Imaging       Date:  2004-10       Impact factor: 3.000

5.  Improved visualization of delayed perfusion in lung MRI.

Authors:  Frank Risse; Monika Eichinger; Hans-Ulrich Kauczor; Wolfhard Semmler; Michael Puderbach
Journal:  Eur J Radiol       Date:  2009-08-26       Impact factor: 3.528

6.  Pulmonary perfusion: qualitative assessment with dynamic contrast-enhanced MRI using ultra-short TE and inversion recovery turbo FLASH.

Authors:  H Hatabu; J Gaa; D Kim; W Li; P V Prasad; R R Edelman
Journal:  Magn Reson Med       Date:  1996-10       Impact factor: 4.668

7.  Dose reduction for CT in children with cystic fibrosis: is it feasible to reduce the number of images per scan?

Authors:  Pim A de Jong; Yasutaka Nakano; Maarten H Lequin; Harm A W M Tiddens
Journal:  Pediatr Radiol       Date:  2005-10-25

8.  [A software program for quantitative analysis of alveolar oxygen partial pressure (p(A)O(2)) with oxygen-sensitive (3)He-MRI].

Authors:  F Lehmann; B Eberle; K Markstaller; K K Gast; J Schmiedeskamp; P Blümler; H-U Kauczor; W G Schreiber
Journal:  Rofo       Date:  2004-10

9.  Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

Authors:  Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2009-04-16       Impact factor: 21.405

10.  Non-contrast-enhanced perfusion and ventilation assessment of the human lung by means of fourier decomposition in proton MRI.

Authors:  Grzegorz Bauman; Michael Puderbach; Michael Deimling; Vladimir Jellus; Christophe Chefd'hotel; Julien Dinkel; Christian Hintze; Hans-Ulrich Kauczor; Lothar R Schad
Journal:  Magn Reson Med       Date:  2009-09       Impact factor: 4.668

View more
  8 in total

Review 1.  Chest imaging in cystic fibrosis studies: What counts, and can be counted?

Authors:  Rhonda Szczesniak; Lidija Turkovic; Eleni-Rosalina Andrinopoulou; Harm A W M Tiddens
Journal:  J Cyst Fibros       Date:  2016-12-28       Impact factor: 5.482

2.  Structural and perfusion magnetic resonance imaging of the lung in cystic fibrosis.

Authors:  Christina Amaxopoulou; Ralph Gnannt; Kai Higashigaito; Andreas Jung; Christian J Kellenberger
Journal:  Pediatr Radiol       Date:  2017-11-15

Review 3.  Computed tomography dose optimisation in cystic fibrosis: A review.

Authors:  Helena Ferris; Maria Twomey; Fiachra Moloney; Siobhan B O'Neill; Kevin Murphy; Owen J O'Connor; Michael Maher
Journal:  World J Radiol       Date:  2016-04-28

Review 4.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

5.  The communication of the radiation risk from CT in relation to its clinical benefit in the era of personalized medicine: part 2: benefits versus risk of CT.

Authors:  Sjirk J Westra
Journal:  Pediatr Radiol       Date:  2014-10-11

Review 6.  Novel outcome measures for clinical trials in cystic fibrosis.

Authors:  Harm A W M Tiddens; Michael Puderbach; Jose G Venegas; Felix Ratjen; Scott H Donaldson; Stephanie D Davis; Steven M Rowe; Scott D Sagel; Mark Higgins; David A Waltz
Journal:  Pediatr Pulmonol       Date:  2014-12-30

Review 7.  Pneumonia in normal and immunocompromised children: an overview and update.

Authors:  Hedieh K Eslamy; Beverley Newman
Journal:  Radiol Clin North Am       Date:  2011-09       Impact factor: 2.303

8.  VISIBILITY OF STRUCTURES OF RELEVANCE FOR PATIENTS WITH CYSTIC FIBROSIS IN CHEST TOMOSYNTHESIS: INFLUENCE OF ANATOMICAL LOCATION AND OBSERVER EXPERIENCE.

Authors:  Carin Meltzer; Magnus Båth; Susanne Kheddache; Helga Ásgeirsdóttir; Marita Gilljam; Åse Allansdotter Johnsson
Journal:  Radiat Prot Dosimetry       Date:  2016-02-03       Impact factor: 0.972

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.